01—Abstract
Summary
Summary of the 8-K filed May 8, 2026. Cited figures are marked; the original filing is the authoritative source.
On May 7, 2026, BridgeBio Pharma, Inc. entered into an Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC establishing an at-the-market offering program under which the Company may sell shares of its common stock, par value $0.001a per share, having an aggregate offering price of up to $500,000,000.
The Company is not obligated to make any sales, and either the Company or the Sales Agents may suspend or terminate the offering upon notice. The Sales Agents will act on a best efforts basis, and the Company will pay them a commission of up to 3.0%b of gross proceeds from any shares sold. The offering is made under a registration statement on Form S-3ASR (File No. 333-295678) that the Company filed on May 7, 2026 under Rule 415 of the Securities Act.
The filing also discloses that, in connection with the new agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC) to terminate the Equity Distribution Agreement dated May 4, 2023, effective May 7, 2026. The filing is a capital-markets administrative update rather than an operational or clinical disclosure. It establishes financing flexibility of up to $500 millionc for investors to monitor, but it does not state how much, if any, stock has been sold or the intended use of proceeds.
02—Key points
Key Highlights
- Entered into an Equity Distribution Agreement on May 7, 2026 with Goldman Sachs & Co. LLC and Leerink Partners LLC for an at-the-market offering program.
- Program covers up to $500,000,000 aggregate offering price of common stock, par value $0.001 per share, sold at the Company's discretion.
- Company is not obligated to sell any shares, and either party may suspend or terminate the offering upon notice.
- Sales Agents will act on a best efforts basis; the Company will pay a commission of up to 3.0% of gross proceeds.
- Shares are offered under a Form S-3ASR registration statement (File No. 333-295678) filed May 7, 2026 under Rule 415.
- Terminated the prior Equity Distribution Agreement dated May 4, 2023 with Goldman Sachs and Leerink Partners, effective May 7, 2026.
- Exhibit 1.1 contains the full Equity Distribution Agreement, incorporated by reference from the registration statement.
03—Questions
Frequently Asked Questions
How large is the new at-the-market offering program?
The Equity Distribution Agreement covers placement shares with an aggregate offering price of up to $500,000,000 of BridgeBio common stock.
Is BridgeBio required to sell shares under this program?
No. The filing states the Company is not obligated to make any sales of common stock, and the Sales Agents are not required to sell any specific number or dollar amount. The Company or the Sales Agents may suspend or terminate the offering upon notice.
What does BridgeBio pay the sales agents?
The Company will pay the Sales Agents a commission of up to 3.0% of the gross proceeds of any Placement Shares sold through them under the agreement.
What happened to the previous equity distribution agreement?
The Company agreed with Goldman Sachs and Leerink Partners to terminate its Equity Distribution Agreement dated May 4, 2023, effective May 7, 2026, in connection with entering the new agreement.
Does this filing say how the proceeds will be used?
No. The filing describes the at-the-market program and its terms but does not state the intended use of any proceeds or how many shares, if any, have been sold.
04—Continue